PTPMT1

Across TCGA pan-cancer cohorts, PTPMT1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PTPMT1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PTPMT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PTPMT1 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

LIHC, HNSC, and BLCA are the cancer types where PTPMT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTPMT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.956	<.001	9	view →
HNSC	Male	III,IV	+0.710	<.001	9	view →
BLCA	Male	All	+0.823	<.001	8	view →
COAD	Female	II,III,IV	+0.721	<.001	8	view →
STAD	All	II,III,IV	+0.567	<.001	7	view →
KIRC	Male	II,III,IV	−0.342	<.001	6	view →
CHOL	Female	All	+1.606	<.001	5	view →
KICH	All	All	−0.556	<.001	5	view →
ESCA	All	All	+0.607	.005	2	view →
BRCA	All	IV	−0.410	.038	2	view →
PRAD	All	All	+0.211	.024	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PTPMT1–LIHC

Open the LIHC breakdown →